Advanced search
Publication Cover
Journal of Medical Economics Volume 20, 2017 - Issue 2
Submit an article Journal homepage
2,572
Views
16
CrossRef citations to date
0
Altmetric
Oncology

Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer

Marjan MassoudiAstellas Pharma, Inc., Northbrook, IL, USA; Correspondence[email protected]
,
Mark BalkMedivation, Inc., San Francisco, CA, USA;
,
Hongbo YangAnalysis Group, Boston, MA, USA
,
Cat N. BuiAstellas Pharma, Inc., Northbrook, IL, USA;
,
Bhavik J. PandyaAstellas Pharma, Inc., Northbrook, IL, USA;
,
Jenny GuoAnalysis Group, Boston, MA, USA
,
Yan SongAnalysis Group, Boston, MA, USA
,
Eric Q. WuAnalysis Group, Boston, MA, USA
,
Bruce BrownAstellas Pharma, Inc., Northbrook, IL, USA;
,
Arie BarlevMedivation, Inc., San Francisco, CA, USA;
&
Scott FlandersAstellas Pharma, Inc., Northbrook, IL, USA;
show all
Pages 121-128 | Received 23 May 2016, Accepted 24 Aug 2016, Published online: 16 Sep 2016

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Mohamad Moussa, Athanasios Papatsoris, Despoina Sryropoulou, Mohamed Abou Chakra, Athanasios Dellis & Lazaros Tzelves. (2021) A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer. Expert Opinion on Pharmacotherapy 22:13, pages 1685-1728.
Read now
Alberto Bretoni, Lucrezia Ferrario & Emanuela Foglia. (2019) HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer. ClinicoEconomics and Outcomes Research 11, pages 283-300.
Read now
Yazan K. Barqawi, Matthew E. Borrego, Melissa H. Roberts & Ivo Abraham. (2019) Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance. Journal of Medical Economics 22:11, pages 1202-1209.
Read now
Yusuke Ito & Marianne D Sadar. (2018) Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens. Research and Reports in Urology 10, pages 23-32.
Read now

Articles from other publishers (12)

Hiroyuki Okumura, Sachie Inoue, Shevani Naidoo, Stefan Holmstrom & Hideyuki Akaza. (2021) Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer in Japan. Japanese Journal of Clinical Oncology 51:8, pages 1319-1329.
Crossref
Amanda Pereira-Salgado, Edmond Michael Kwan, Ben Tran, Peter Gibbs, Johann De Bono & Maarten IJzerman. (2021) Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?. European Urology Focus 7:4, pages 752-763.
Crossref
Kristine Kreis, Dirk Horenkamp-Sonntag, Udo Schneider, Jan Zeidler, Gerd Glaeske & Lothar Weissbach. (2020) Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study. PharmacoEconomics - Open 5:2, pages 299-310.
Crossref
Dan Su, Bin Wu & Lizheng Shi. (2021) Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer. Frontiers in Pharmacology 11.
Crossref
Tsung‐Ying Lee, Shihchen Kuo, Chen‐Yi Yang & Huang‐Tz Ou. (2020) Cost‐effectiveness of long‐acting insulin analogues vs intermediate/long‐acting human insulin for type 1 diabetes: A population‐based cohort followed over 10 years . British Journal of Clinical Pharmacology 86:5, pages 852-860.
Crossref
Krishnan Ramaswamy, Stanislav Lechpammer, Jack Mardekian, Ahong Huang, Neil M. Schultz, Rickard Sandin, Li Wang, Onur Baser & Daniel J. George. (2020) Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone. Advances in Therapy 37:5, pages 2083-2097.
Crossref
Neil M. SchultzKen O’DayRebecca SugarmanKrishnan Ramaswamy. (2020) Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer. Journal of Managed Care & Specialty Pharmacy 26:4, pages 538-549.
Crossref
Thomas Grochtdreis, Hans-Helmut König, Alexander Dobruschkin, Gunhild von Amsberg & Judith Dams. (2018) Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review. PLOS ONE 13:12, pages e0208063.
Crossref
Neil M. Schultz, Neal D. Shore, Simon Chowdhury, Laurence H. Klotz, Raoul S. Concepcion, David F. Penson, Lawrence I. Karsh, Hongbo Yang, Bruce A. Brown, Arie Barlev & Scott C. Flanders. (2018) Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials. BMC Urology 18:1.
Crossref
Lesley J. Scott. (2018) Enzalutamide: A Review in Castration-Resistant Prostate Cancer. Drugs 78:18, pages 1913-1924.
Crossref
Jan Norum & Carsten Nieder. (2017) Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence. PharmacoEconomics 35:12, pages 1223-1236.
Crossref
Esse I. H. Akpo, Irshaad R. Jansen, Edith Maes & Steven Simoens. (2017) Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer. Frontiers in Pharmacology 8.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.